Pharmaceutical - edoxaban, Research

Filter

Current filters:

edoxabanResearch

Popular Filters

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

10-07-2014

USA-based Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Japanese…

andexanet alfaCardio-vascularDaiichi SankyoedoxabanJapanLicensingPharmaceuticalPortola PharmaceuticalsResearchSavaysaUSA

Daiichi Sankyo files Savaysa for US approval; collaborates with Virtici and Celdara Medical

Daiichi Sankyo files Savaysa for US approval; collaborates with Virtici and Celdara Medical

10-01-2014

Japanese drug major Daiichi Sankyo has filed a New Drug Application for its investigational, oral, once-daily…

Cardio-vascularCeldara MedicalDaiichi SankyoedoxabanNorth AmericaPharmaceuticalRegulationResearchSavaysaUSAVirtici

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

Daiichi Sankyo's edoxaban shows comparable efficacy to warfarin in Phase III trial

20-11-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that its blood thinner edoxaban met the primary efficacy…

Asia-PacificCardio-vascularDaiichi SankyoedoxabanPharmaceuticalResearchWarfarin Sodium

Positive Ph III results for Daiichi Sankyo's edoxaban in VTE

02-09-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has released encouraging results from the global Phase…

Cardio-vascularDaiichi SankyoedoxabanLixianaPharmaceuticalResearch

Daiichi Sankyo to support Phase I clinical study of anticoagulant activity reverser for edoxaban

25-04-2013

USA-based Perosphere and Japanese drug major Daiichi Sankyo(TYO: 4568) have entered into a clinical trial…

Cardio-vascularDaiichi SankyoedoxabanPER977PharmaceuticalResearch

Back to top